Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
about
Calcium channel blockers for pulmonary arterial hypertensionCalcium channel blockers for pulmonary arterial hypertensionInterventions for deliberately altering blood pressure in acute strokeInfluence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarctionGrapefruit juice-drug interactionsOverview of Antagonists Used for Determining the Mechanisms of Action Employed by Potential Vasodilators with Their Suggested Signaling PathwaysMedical management of chronic stable anginaAdjunctive treatment in patients treated with thrombolytic therapyAcute coronary syndrome in the prehospital phaseOptimal medical management of anginaAmlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J)Sublingual nifedipine in elderly patients: even a low dose induces myocardial ischaemiaNifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Influence of permeating ions on Kv1.5 channel block by nifedipine.Interventions for deliberately altering blood pressure in acute stroke.Sublingual nifedipine in human pregnancy.Comparison of effect between nitrates and calcium channel antagonist on vascular function in patients with normal or mildly diseased coronary arteries.Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus.Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.Discovery and Development of Calcium Channel Blockers.Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study.Non ST-elevation acute coronary syndrome.Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension.Ivabradine: the evidence of its therapeutic impact in angina.Observation and experiment on the cusp of collaboration: a parallel examination of clinical pharmacology and pharmacoepidemiology.Treatment of diabetic patients with hypertension.Coronary heart disease prevention As the primary goal in contemporary trials in the treatment of hypertension.The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study GroupHigh levels of endorphin and related pathologies of veterinary concern. A review.Pathophysiologic therapeutic targets in hypertension: a cardiological point of view.The L-type calcium channel in the heart: the beat goes onAntihypertensive drugs and sympathetic nervous system.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventBeneficial Effect of Efonidipine, an L- and T-Type Dual Calcium Channel Blocker, on Heart Rate and Blood Pressure in Patients With Mild-to-Moderate Essential Hypertension.A critique of hypertension treatment trials and of their evaluation.Meta-analyses of antihypertensive therapy: Are some of them misleading?The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension.Postmenopausal hypertension: role of the Renin-Angiotensin system.Family physicians' and general practitioners' approaches to drug management of diabetic hypertension in primary care.
P2860
Q24187010-DEBA5E26-892E-4EA1-B154-6AA0E69BDC85Q24200926-30073E8E-A339-4D6A-8E2F-ACEBF7C4CE0FQ24241232-C41033AB-68D3-4519-9B5A-69C55CB1A163Q24550610-CB320ED4-C079-4F56-8A10-D70E0CD65D02Q24683430-9C15B370-37BB-4E24-B389-47AF3B639327Q26752401-73D2DDF1-E1E1-422F-8C09-656CA47FE385Q26773268-B2FF80A7-8385-4867-B379-0E59657A3FECQ28168234-40256C86-27D2-4113-9958-7B9EE7970389Q28189866-B0F8096D-4E5E-4AC0-9E00-7C36F312B06FQ28196421-3B310912-E561-40D4-B7F6-49D1F4F68097Q28200627-4F351BD3-9D6F-4142-BFA7-758780165D41Q28368131-27E38BCC-DD47-4011-A79D-938910C8F3BCQ28578027-08D20F47-678F-41C5-967B-40D8DEEC4668Q30311015-6C7E0374-C0E0-47E8-929D-370281A8EC9CQ31940163-32101E0A-A4F3-4C57-8176-4BA9DD45AA08Q32025822-89B3CCEB-5941-4ABC-8D84-6EC4EB7D94FEQ32172932-6F017364-E656-42FC-B7B2-2B12F1D6C7B7Q33327002-4D9786FB-A223-4394-BBF8-D57D916D1839Q33643752-4C96AD21-ABF9-4D44-9969-094E80C15B29Q33711285-2AE6564B-D6EA-420B-B61C-6BD16445AD69Q33734936-985B6654-9A02-48D6-A2BF-E23B841CFA15Q33739104-61DA51A7-33A0-433A-BF97-CC0DD1A4A9EAQ33846765-8C1AEADF-F02E-4567-9F55-566608698B88Q33929765-56C05E29-4BEB-406B-AE3D-0F9EB6CB8B26Q33973963-023D0D11-06D8-4168-A688-7CA1C91278ABQ34024124-3945525B-13F5-4F4B-8942-0685D35E4810Q34028230-2B1CF18B-421D-4AB3-95A5-C37E6E21AC67Q34028647-D949CD74-5DB3-49AA-A7AC-018CCA3646BCQ34029556-8D14BD7A-0E3A-4E35-8865-39F632413221Q34098400-E7CB69A5-5D06-40DB-93FD-CA9912D60A9BQ34142036-4807E803-3F7F-49C4-9915-78BD83F4F1E5Q34160273-D343CA38-5514-49D2-B78D-754AC3DFBCF0Q34196370-AFA36FDA-7103-41F0-A2A9-0A16D964989EQ34254787-9C466F41-4F5C-4BE2-AEFB-B77F994C1455Q34297915-A701D614-3936-41AB-9815-D778D0499BB7Q34328239-527596EB-96BE-4E19-8A45-303C434632C6Q34365037-89B94FE6-B27A-420D-8B68-CAF3C7CB3D52Q34401862-9E50F433-2D6E-4703-B656-88E293E28E52Q34402355-07716817-6D60-49CD-8434-A37D4CBE1E2DQ34554070-7D4C5281-3BF2-481D-B0AE-6B0CE3741B90
P2860
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@ast
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@en
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@nl
type
label
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@ast
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@en
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@nl
prefLabel
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@ast
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@en
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@nl
P2093
P356
P1433
P1476
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
@en
P2093
P304
P356
10.1161/01.CIR.92.5.1326
P407
P577
1995-09-01T00:00:00Z